TICKERNERD
Menu
CVMCVMHealthcare · Biotechnology

CVM Stock Forecast: CEL-SCI Corp. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$1.61
−0.62% on the day

The 2 Wall Street analysts covering CEL-SCI Corp. hold a median 12-month price target of $13 — +676.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 22 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$28.5M
Ticker Nerd rank
39/ 100
Median analyst target
$13
Analysts covering
2
Revenue$0.0
Operating income−$5.6M
Net income−$5.7M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.5%
1M
−5.3%
YTD
−69.4%
1Y
−82.6%
From 52W high
−82.6%
From 52W low
+66.0%
$0.97
$9.27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CEL-SCI Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
39/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Accruals
85
Growth
69
Issuance
53
Value
39
Quality
33
Revisions
32
Volatility
17
Momentum
10

Size (85): Smaller than most of the companies we track.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CVM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26CVMHigh $15Median $13Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $10Median $13High $15

The green dot is the last close — the median target sits +676.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 July 2023EF HuttonReiteratesBuy—
9 Mar 2023EF HuttonReiteratesBuy—
17 Feb 2023EF HuttonAssumesBuy$10
29 Dec 2022EF HuttonMaintainsBuy—
25 Aug 2022EF HuttonInitiatesBuy—
7 Apr 2022EF HuttonInitiatesBuy—
13 Jan 2020H.C. WainwrightInitiatesBuy—
13 Jan 2020HC Wainwright & Co.InitiatesBuy—
20 Feb 2013Taglich BrothersInitiatesSpeculative Buy—
13 Feb 2013Chardan CapitalInitiatesBuy—
14 Jan 2013Laidlaw & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CVM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

CVM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, CEL-SCI Corp. returned −82.6% against +15.6% for the S&P 500, dividends included.

CVM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26CVMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CVM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

CEL-SCI Corp. (CVM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
2.6×

Cheaper than 34% of US stocks

EV / EBITDA
−1.5×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−252.5%

Higher than 6% of US stocks

Return on assets
−66.8%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CEL-SCI Corp. (CVM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CEL-SCI Corp. has a market value of $28.5M and an enterprise value of $29.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$22.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$16.8M.

  • Shares outstanding: 17.6M.

  • Trailing P/E: −0.3×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • CEL-SCI Corp. employs 0 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

CVM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CVMCEL-SCI Corp.$28.5M39
ABVCABVC BioPharma, Inc.$27.9M15
RNAZTransCode Therapeutics, Inc.$29.0M21
ATOSAtossa Therapeutics, Inc.$27.1M27
BSEMBioStem Technologies, Inc.$29.6M62
ALGSAligos Therapeutics, Inc.$29.8M74
ESLAEstrella Immunopharma, Inc.$30.6M29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CEL-SCI Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CVM news & analysis

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology

Business Wire · 15 Sept 2026positive

CEL-SCI announced it has been invited to deliver a keynote address on its immunotherapy candidate Multikine at the 6th World Congress on Otology, Rhinology and Laryngology. The invitation was announced in a Business Wire press release.

Why it matters — CVM watchers would care because the keynote invitation gives Multikine international visibility and recognition at a leading medical congress focused on head and neck-related fields.

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Business Wire · 17 Aug 2026neutral

CEL-SCI announced its financial results for the three months ended June 30, 2026, in its fiscal third quarter report. The company also provided an update on recent corporate and clinical developments related to its lead candidate, Multikine.

Why it matters — CVM watchers monitor these quarterly results and clinical updates to track progress on Multikine and the company's financial standing.

CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study

Business Wire · 4 Aug 2026positive

A study on CEL-SCI's Multikine immunotherapy was published in the peer-reviewed journal Oral Oncology, supporting the company's biomarker strategy and suggesting a potential overall survival benefit ahead of a confirmatory registration study in head and neck cancer.

Why it matters — Peer-reviewed publication of data supporting Multikine's biomarker strategy adds scientific credibility as CEL-SCI prepares for its confirmatory registration study in head and neck cancer.

Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients

Business Wire · 30 July 2026positive

CEL-SCI announced that a leading oncology journal has accepted for publication new Phase 3 data on its investigational drug Multikine, demonstrating an overall survival benefit in underserved head and neck cancer patients.

Why it matters — A peer-reviewed publication of Phase 3 data showing a survival benefit could lend scientific credibility to Multikine and support the company's regulatory and commercial efforts.

FAQ

Frequently asked questions about CVM stock

What is the CVM stock price forecast for 2026-2027?

The 2 Wall Street analysts covering CEL-SCI Corp. have a median 12-month price target of $13, with estimates ranging from $10 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVM stock a buy right now?

Of the 2 analysts covering CEL-SCI Corp., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CEL-SCI Corp. 39 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVM?

As at 22 Oct 2026, CEL-SCI Corp. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

Will CVM stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +676.4% from the last close, and Ticker Nerd's factor model ranks CEL-SCI Corp. 39 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVM stock forecast for 2030?

No analyst covering CEL-SCI Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $15 over the next 12 months.

How has CVM stock performed over the past year?

CEL-SCI Corp. returned -82.6% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CEL-SCI Corp. do?

CEL-SCI Corporation is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and other diseases. The company’s current work centers on immune-based treatments designed to help the body recognize and respond to disease, with research and development spanning oncology, autoimmune conditions, and infectious diseases.

What is the latest news on CVM?

The most recent item we track (Business Wire, 15 Sept 2026): "CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology". CEL-SCI announced it has been invited to deliver a keynote address on its immunotherapy candidate Multikine at the 6th World Congress on Otology, Rhinology and Laryngology. The invitation was announced in a Business Wire press release.

Company

About CEL-SCI Corp.

CEL-SCI Corporation is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and other diseases. The company’s current work centers on immune-based treatments designed to help the body recognize and respond to disease, with research and development spanning oncology, autoimmune conditions, and infectious diseases. Its lead programs include Multikine, an investigational therapy for head and neck cancer, and the LEAPS platform, which supports the creation of targeted immune-modulating candidates. CEL-SCI also combines drug discovery, development, and manufacturing capabilities for complex biological substances, making it a specialized participant in the life sciences sector. Headquartered in Vienna, Virginia, CEL-SCI Corporation operates as a research-driven company within the biotechnology market, where its pipeline is aimed at advancing novel therapeutic approaches through immunology.

CEO Mr. Geert R. Kersten Esq. · United States · https://cel-sci.com